PCV for oligodendroglial tumors: in search of prognostic factors for response and survival.
BACKGROUND
We report survival and pretreatment prognostic factors for survival and chemosensitivity in 53 oligodendrogliomas treated with PCV (procarbazine, lomustine and vincristine) chemotherapy.


METHODS
A total of 53 patients with histologically proven oligodendroglioma, anaplastic oligodendroglioma or oligo-astrocytoma and treated with PCV were extracted from the London Regional Cancer Center database. A retrospective review was conducted to evaluate overall survival and pretreatment prognostic factors for survival and chemosensitivity.


RESULTS
The median survival time from diagnosis was 123.6 months. The overall five- and ten-year survival rates were 72.7% and 52.7% respectively. Age <40, seizure as an initial symptom, absence of cognitive deficit and presence of a homogeneous hypodense lesion without contrast enhancement on the initial pretreatment CT scan were all factors independently associated with favorable outcome. The presence of increased cellularity, pleomorphism, mitosis, vascular proliferation and grading as an anaplastic lesion using these surrogates on pathological assessment, were all associated with an unfavorable outcome in univariable analysis. In multivariable analysis, only the anaplastic grading and presence of increased cellularity were significant determinants of unfavorable survival. The only factor adversely associated with chemosensitivity was the presence of a focal symptom at presentation.


CONCLUSIONS
Overall survival is significantly longer in oligodendroglial lesions than in fibrillary astrocytic tumors. A two tier grading system using standard morphological features seems accurate in predicting outcome in these patients. The presence of a neoplastic astrocytic component does not seem to impact the outcome. No clinical, radiological or pathological factor could be identified to reliably predict chemotherapy response.
Fortin
D
D
Department of Neurosurgery and Neuro-oncology, Centre Universitaire de Santé de l'Estrie, Sherbrooke University, Québec, Canada.
Macdonald
D R
DR
Stitt
L
L
Cairncross
J G
JG
D000328:Adult; D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy* / Q000523:psychology; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000523:psychology; D002945:Cisplatin / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000209:etiology / Q000523:psychology; D018450:Disease Progression; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D015999:Multivariate Analysis; D009837:Oligodendroglioma / Q000188:drug therapy* / Q000523:psychology; D017239:Paclitaxel / Q000627:therapeutic use*; D011379:Prognosis; D016019:Survival Analysis; D043823:Taxoids; D014747:Vinblastine / Q000031:analogs & derivatives / Q000627:therapeutic use*
D043823:Taxoids; D014747:Vinblastine; D017239:Paclitaxel; D002945:Cisplatin